Sign up USA
Proactive Investors - Run By Investors For Investors

VolitionRX to expedite clinical trials after opening state-of-the-art lab

Volition is a multi-national life sciences company developing simple, easy to use blood-based cancer tests to accurately diagnose a range of cancers
no_picture_pai.jpg
The facility was opened on time and within budget

VolitionRx Ltd (NYSEMKT:VNRX) has opened a new research and development facility in Belgium this week.

The US-listed European cancer diagnostics group said the purpose-built laboratory would enable it to increase capacity to carry out clinical trials and to expand its scientific team.

A more modern lab and a bigger lab team should lead to trials taking less time.

WATCH a video showcasing the start-of-the art lab

READ the VolitionRX investment case

"Our capacity to run large clinical trials has increased significantly with this five-fold increase in laboratory space. This will facilitate large scale manual and automated robotic testing. We will now have the ability to work on several large trials at the same time, namely: the front-line screening colorectal cancer tests and  lung, prostate and pancreatic cancer," said Dr Marielle Herzog, Research and Development Director of Volition.

Volition's Belgian arm acquired the 19,000 square foot property for €1.2mln – about US$1.29mln.

Volition's research and development activities are currently centered in Belgium, with additional offices in London, New York, Texas and Singapore, as the company focuses on bringing its diagnostic products to market first in Europe, then in the US and ultimately, worldwide.

John-H.jpg
Why Invest In VolitionRx? Read More Here

Register here to be notified of future VNRX Company articles
View full VNRX profile

VolitionRx Timeline

Newswire
April 11 2017

Related Articles

viagra2.jpg
September 07 2016
It means Futura now has a differentiated product in a market worth US$5bn that , currently dominated by top-selling drugs, such as Viagra and Cialis, that have limitations.
biotechLatest.jpg
March 28 2017
2017 is going to be quite action packed we believe we have positioned the company for when RNA interference transforms from a technology to its promise of a new class of therapeutics - boss Ali Mortazavi.
cancer cells
February 10 2017
It has already got £7.2mln of the £14.9mln it is looking to raise, which will help fund the development of two promising cancer drug candidates: RXC004 and RXC005
Copyright © Proactiveinvestors.com, 2017. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use